JPH06510275A - 色素脱失疾患を治療するための組成物および方法 - Google Patents

色素脱失疾患を治療するための組成物および方法

Info

Publication number: JPH06510275A
Authority: JP; Japan
Prior art keywords: pseudocatalase; skin; tyrosinase; drug composition; topical
Prior art date: 1991-05-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP4510487A

Other languages

English (en)

Japanese (ja)

Inventor

ウッド、ジョン・マーティン

シャルロイター、カーリン・ウタ

Original Assignee

スティーフェル・ラボラトリーズ・インコーポレーテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-15

Filing date

1992-05-15

Publication date

1994-11-17

1992-05-15 Application filed by スティーフェル・ラボラトリーズ・インコーポレーテッド filed Critical スティーフェル・ラボラトリーズ・インコーポレーテッド

1994-11-17 Publication of JPH06510275A publication Critical patent/JPH06510275A/ja

Status Pending legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 14
238000000034 method Methods 0.000 title claims description 12
208000026748 Hypopigmentation disease Diseases 0.000 title 1
108010036322 pseudocatalase Proteins 0.000 claims description 24
201000010099 disease Diseases 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
102000003425 Tyrosinase Human genes 0.000 claims description 12
108060008724 Tyrosinase Proteins 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 11
230000000699 topical effect Effects 0.000 claims description 11
230000035614 depigmentation Effects 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
-1 transition metal coordination complex Chemical class 0.000 claims description 9
108010053835 Catalase Proteins 0.000 claims description 7
102000016938 Catalase Human genes 0.000 claims description 7
WMOSTDJFFWYKNF-UHFFFAOYSA-L hydrogen carbonate;manganese(2+) Chemical compound [Mn+2].OC([O-])=O.OC([O-])=O WMOSTDJFFWYKNF-UHFFFAOYSA-L 0.000 claims description 7
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims description 5
239000000049 pigment Substances 0.000 claims description 5
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
229910001424 calcium ion Inorganic materials 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
229910021380 Manganese Chloride Inorganic materials 0.000 claims description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 2
239000003446 ligand Substances 0.000 claims description 2
239000011565 manganese chloride Substances 0.000 claims description 2
235000002867 manganese chloride Nutrition 0.000 claims description 2
235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
239000008009 topical excipient Substances 0.000 claims description 2
VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 claims 1
WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims 1
150000004696 coordination complex Chemical class 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
230000000485 pigmenting effect Effects 0.000 claims 1
239000002884 skin cream Substances 0.000 claims 1
229910052723 transition metal Inorganic materials 0.000 claims 1
210000003491 skin Anatomy 0.000 description 10
206010047642 Vitiligo Diseases 0.000 description 9
208000012641 Pigmentation disease Diseases 0.000 description 7
230000019612 pigmentation Effects 0.000 description 6
206010015150 Erythema Diseases 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
241000519995 Stachys sylvatica Species 0.000 description 5
239000006071 cream Substances 0.000 description 5
230000003902 lesion Effects 0.000 description 4
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000008099 melanin synthesis Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
231100000321 erythema Toxicity 0.000 description 2
239000008309 hydrophilic cream Substances 0.000 description 2
229960003511 macrogol Drugs 0.000 description 2
229910052748 manganese Inorganic materials 0.000 description 2
239000011572 manganese Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000008961 swelling Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 1
208000033764 Acatalasemia Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000511343 Chondrostoma nasus Species 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101000606090 Homo sapiens Tyrosinase Proteins 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000006187 Onycholysis Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
241000255969 Pieris brassicae Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010042496 Sunburn Diseases 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
230000037338 UVA radiation Effects 0.000 description 1
208000003486 acatalasia Diseases 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
238000003287 bathing Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000009519 contusion Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000007854 depigmenting agent Substances 0.000 description 1
230000008021 deposition Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
231100000040 eye damage Toxicity 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000004313 glare Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000003810 hyperpigmentation Effects 0.000 description 1
208000000069 hyperpigmentation Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000011656 manganese carbonate Substances 0.000 description 1
235000006748 manganese carbonate Nutrition 0.000 description 1
229940093474 manganese carbonate Drugs 0.000 description 1
229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
229960004469 methoxsalen Drugs 0.000 description 1
SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
230000002165 photosensitisation Effects 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
239000008213 purified water Substances 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000002468 redox effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000009759 skin aging Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Transceivers (AREA)
Mobile Radio Communication Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP4510487A 1991-05-15 1992-05-15 色素脱失疾患を治療するための組成物および方法 Pending JPH06510275A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB919110652A GB9110652D0 (en)	1991-05-15	1991-05-15	Composition and method of treating depigmentation disorders
GB9110652.6		1991-05-15
PCT/GB1992/000878 WO1992020354A1 (en)	1991-05-15	1992-05-15	Composition and method of treating depigmentation disorders

Publications (1)

Publication Number	Publication Date
JPH06510275A true JPH06510275A (ja)	1994-11-17

Family

ID=10695131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP4510487A Pending JPH06510275A (ja)	1991-05-15	1992-05-15	色素脱失疾患を治療するための組成物および方法

Country Status (20)

Country	Link
US (1)	US5433942A (de)
EP (1)	EP0584171B1 (de)
JP (1)	JPH06510275A (de)
KR (1)	KR100190978B1 (de)
AT (1)	ATE183097T1 (de)
AU (1)	AU649543B2 (de)
CA (1)	CA2102514A1 (de)
DE (1)	DE69229780T2 (de)
ES (1)	ES2137185T3 (de)
GB (1)	GB9110652D0 (de)
GR (1)	GR3031483T3 (de)
IE (1)	IE69854B1 (de)
IL (1)	IL101871A (de)
MY (1)	MY108848A (de)
NZ (1)	NZ242748A (de)
PH (1)	PH30792A (de)
SG (1)	SG45381A1 (de)
TW (1)	TW201695B (de)
WO (1)	WO1992020354A1 (de)
ZA (1)	ZA923561B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6139850A (en) *	1994-12-21	2000-10-31	Cosmederm Technologies	Formulations and methods for reducing skin irritation
US6455076B1 (en)	1994-12-21	2002-09-24	Gary S. Hahn	Formulations and methods for reducing skin irritation
US7404967B2 (en) *	1994-12-21	2008-07-29	Cosmederm, Inc.	Topical product formulations containing strontium for reducing skin irritation
EP0799018A4 (de) *	1994-12-21	2000-03-29	Cosmederm Technologies	Formulierungen und verfahren zur verminderung von hautirritationen
GB2307175A (en) *	1995-11-14	1997-05-21	Steifel Lab Inc	Topical composition comprising a transition metal and bicarbonate ions, particularly for the promotion of pigmentation
US6979327B2 (en) *	2000-02-25	2005-12-27	Mount Sinai School Of Medicine	Treatment of vitiligo
DE10043466A1 (de) *	2000-09-04	2002-03-28	Johannes Wohlrab	Manganverbindungen enthaltende Zubereitung zur topischen Applikation und deren Verwendungen
FR2814945B1 (fr) *	2000-10-09	2003-02-14	Oreal	Procede de traitement de la canitie
US6630130B1 (en)	2001-07-16	2003-10-07	Pearl Grimes	Sunless tanning cream
FR2839449B1 (fr) *	2002-05-13	2006-12-08	Oreal	Utilisation d'au moins un complexe de metal comme desquamant
US20030224028A1 (en) *	2002-05-13	2003-12-04	Societe L'oreal S.A.	Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal
US20040148712A1 (en)	2002-11-29	2004-08-05	Francis Pruche	Composition for coloring a keratin material, comprising at least two components, and coloring processes
JP4687436B2 (ja) *	2005-12-13	2011-05-25	ウシオ電機株式会社	エキシマ光治療器

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU71110A1 (de) *	1974-10-15	1976-11-11
ZA786403B (en) *	1977-12-01	1979-10-31	Ici Australia Ltd	Process
AU518946B2 (en) *	1979-02-23	1981-10-29	Kenneth John Hausler	Trace mineral (s) cream
AU544544B2 (en) *	1980-08-20	1985-06-06	Erwin Gunther Walliczek	Cuprous complex for therapeutic use
AU7552981A (en) *	1980-12-08	1982-09-09	Bio-Systems Research Inc.	Anti-viral, anti-bacterial and/or anti fungal composition containing metal oxyalkylate
JPH0196107A (ja) *	1987-10-07	1989-04-14	Kanebo Ltd	皮膚化粧料
JPH02108612A (ja) *	1988-10-19	1990-04-20	Shizen:Kk	二価三価複合鉄塩配合化粧品
EP0424033A3 (en) *	1989-10-19	1991-07-31	Pola Chemical Industries Inc	External skin preparation

1991
- 1991-05-15 GB GB919110652A patent/GB9110652D0/en active Pending
1992
- 1992-05-14 IL IL10187192A patent/IL101871A/xx not_active IP Right Cessation
- 1992-05-14 MY MYPI92000812A patent/MY108848A/en unknown
- 1992-05-15 ES ES92910389T patent/ES2137185T3/es not_active Expired - Lifetime
- 1992-05-15 NZ NZ242748A patent/NZ242748A/xx unknown
- 1992-05-15 CA CA002102514A patent/CA2102514A1/en not_active Abandoned
- 1992-05-15 WO PCT/GB1992/000878 patent/WO1992020354A1/en not_active Ceased
- 1992-05-15 AT AT92910389T patent/ATE183097T1/de not_active IP Right Cessation
- 1992-05-15 SG SG1996005300A patent/SG45381A1/en unknown
- 1992-05-15 AU AU17854/92A patent/AU649543B2/en not_active Ceased
- 1992-05-15 US US08/150,014 patent/US5433942A/en not_active Expired - Fee Related
- 1992-05-15 DE DE69229780T patent/DE69229780T2/de not_active Expired - Fee Related
- 1992-05-15 JP JP4510487A patent/JPH06510275A/ja active Pending
- 1992-05-15 KR KR1019930703445A patent/KR100190978B1/ko not_active Expired - Fee Related
- 1992-05-15 EP EP92910389A patent/EP0584171B1/de not_active Expired - Lifetime
- 1992-05-15 PH PH44350A patent/PH30792A/en unknown
- 1992-05-15 ZA ZA923561A patent/ZA923561B/xx unknown
- 1992-06-04 TW TW081104408A patent/TW201695B/zh active
- 1992-07-01 IE IE921559A patent/IE69854B1/en not_active IP Right Cessation
1999
- 1999-10-08 GR GR990402575T patent/GR3031483T3/el unknown

Also Published As

Publication number	Publication date
IL101871A (en)	1997-01-10
KR100190978B1 (ko)	1999-06-15
IE921559A1 (en)	1992-11-18
ES2137185T3 (es)	1999-12-16
NZ242748A (en)	1995-01-27
GB9110652D0 (en)	1991-07-03
DE69229780T2 (de)	1999-12-16
ZA923561B (en)	1993-04-28
PH30792A (en)	1997-10-17
WO1992020354A1 (en)	1992-11-26
CA2102514A1 (en)	1992-11-16
EP0584171A1 (de)	1994-03-02
TW201695B (de)	1993-03-11
ATE183097T1 (de)	1999-08-15
DE69229780D1 (de)	1999-09-16
IL101871A0 (en)	1992-12-30
EP0584171B1 (de)	1999-08-11
IE69854B1 (en)	1996-10-02
GR3031483T3 (en)	2000-01-31
SG45381A1 (en)	1998-01-16
AU649543B2 (en)	1994-05-26
US5433942A (en)	1995-07-18
MY108848A (en)	1996-11-30
AU1785492A (en)	1992-12-30

Publication	Publication Date	Title
Itkin et al.	2004	δ‐Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome
Issa et al.	2010	Photodynamic therapy: a review of the literature and image documentation
Kennedy et al.	1990	Photodynamic therapy with endogenous protoporphyrin: IX: basic principles and present clinical experience
EP0584178B1 (de)	1996-08-28	Zusammensetzung und methode zur verstärkung der sonnenbräunung
Robinson et al.	1988	Photodynamic therapy: a better treatment for widespread Bowen's disease
Grundmann‐Kollmann et al.	1999	Treatment of severe recalcitrant dermatoses of the palms and soles with PUVA‐bath versus PUVA‐cream therapy
JPH06510275A (ja)	1994-11-17	色素脱失疾患を治療するための組成物および方法
US20080125395A1 (en)	2008-05-29	Compositions and methods for the treatment of skin
CA2133741A1 (en)	1993-10-28	Photochemotherapeutic method using 5-aminolevulinic acid and precursor thereof
EP2236129A2 (de)	2010-10-06	Liposomale pharmazeutische und kosmezeutische ALA-Zusammensetzungen und Behandlungsverfahren
JPH01501627A (ja)	1989-06-08	乾癬治療用組成物
Steinbauer et al.	2010	Photodynamic therapy in dermatology
US7368131B2 (en)	2008-05-06	Method and composition for treating hypopigmentation of the hair and skin
EP0836476B1 (de)	2006-12-20	Retinsäurepropyleneglycolester enthaltender Kosmetikum ZUR ANWENDUNG AUF DER HAUT SOWIE ARZNEIMITTEL ZUR BEHANDLUNG VON Hautkrankheiten, TUMORÖSEN ZELLEN UND BLASEN-ODER NERVENSTÖRUNGEN
Silva et al.	2008	Photodynamic therapy: dermatology and ophthalmology as main fields of current applications in clinic
Han et al.	2016	Observation of clinical efficacy of photodynamic therapy in 3 patients with refractory plaque-stage mycosis fungoides
Zanolli	2003	The modern paradigm of phototherapy
Lanks et al.	1994	Photodynamic enhancement of doxorubicin cytotoxicity
Eber et al.	2018	Photodynamic therapy
Hull et al.	1985	Effect of hematoporphyrin derivative on rabbit corneal endothelial cell function and ultrastructure.
RU94021014A (ru)	1996-08-27	Способ лечения злокачественных опухолей методом фотодинамической терапии
JPH0653664B2 (ja)	1994-07-20	プソラレン誘導体含有薬剤
Gold	2005	Lasers, photodynamic therapy, and the treatment of medical dermatologic conditions
Harth et al.	1996	A case of basal cell carcinoma treated with photodynamic therapy—changes in histological features and bcl-2 expression
Grossweiner	2005	Phototherapy of Skin Disease: Science and Technology